Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Cancer Research at the
Helen F. Graham Cancer Center
& Research Institute

Research Governance

Institutional Review Board (IRB)

All biomedical and behavioral research protocols are reviewed and approved by the ChristianaCare Institutional Review Board in accordance with 21 CFR 50 and 45 CFR 46. The ChristianaCare IRB has been granted a Federalwide Assurance by the Office for Human Research Subject Protection (OHRP) approved through the Department of Health and Human Services (Federalwide Assurance Number FWA00006557). The IRB meets biweekly. ChristianaCare is frequently recognized by auditors for high quality IRB processes. In compliance with federal regulations, ChristianaCare IRB conducts reviews of all protocols at least annually and sometimes, depending on the relative risk of the protocol, more frequently.

Office of Sponsored Programs (OSP)

The ChristianaCare Office of Sponsored Programs (OSP) is the central administrative office responsible for assisting with the processing and submission of sponsored programs at ChristianaCare. This includes grant proposal review and submissions as well as contract and budget processing with pharmaceutical, federal and private foundation sponsors on behalf of ChristianaCare. OSP is responsible for overseeing that all research proposals, contracts and other agreements abide by ChristianaCare and external sponsors research policies and guidelines. Furthermore, the OSP serves to advise and educate the administration and staff on matters of regulatory compliance, federal and internal policies on research, and other research-related issues

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2200, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.